Medical Condition News

RSS

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

SuperGen, Inc. today announced that it has enrolled the first patient in its first in human study of SGI-110, a second-generation hypomethylating agent, in patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

5 Jan 2011

Study finds fusion surgeries designed to alleviate pain from degenerating discs not effective

Alfred O. Bonati, M.D., internationally known orthopedic surgeon and founder of The Bonati Spine Institute, reports that, in his experience, the failure rates for open back surgery, as recently reported by the Ohio Bureau of Workers' Compensation, are not out of line.

5 Jan 2011

American Heart Association partners in global effort to prepare for UN non-communicable diseases summit

The American Heart Association is participating in an international effort to prepare for a United Nations (UN) high-level summit next year on non-communicable diseases (NCDs). These diseases — mainly cardiovascular illnesses including stroke, diabetes, cancer and chronic respiratory conditions — were estimated to cause more than 60 percent of deaths worldwide in 2005.

5 Jan 2011

Soldiers with positive outlook in traumatic situations less likely to suffer anxiety, depression

In the first combat-zone study of its kind, a research team led by Michigan State University found that soldiers with a positive outlook in the most traumatic situations were less likely to suffer health problems such as anxiety and depression.

5 Jan 2011

Neuroscientist says spatial strategies can reduce risk of dementia

Véronique Bohbot, PhD., neuroscientist at the Douglas Mental Health University Institute and associate professor at McGill University, leads studies on navigational strategies. She presented her findings at the recent meeting of the Society for Neuroscience in San Diego, which could bring light into how we can make better use of our hippocampus in order to reduce the risk of dementia.

5 Jan 2011

Predictive value of plasma galectin-3 levels in heart failure patients: Study

BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel diagnostics, today announced the publication of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.

5 Jan 2011

Study shows adolescents who were breastfed at birth have stronger leg muscles

Breast feeding new born babies has lots of advantages in the short and in the long-term for babies. A study has confirmed the recently discovered benefits, which had not been researched until now. Adolescents who are breast fed at birth have stronger leg muscles than those who received artificial milk.

5 Jan 2011

ImmunGene, Cephalon Australia collaborate to advance new class of protein therapeutics

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.

5 Jan 2011

KINAXO, AstraZeneca enter oncology research collaboration

KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms of the agreement, KINAXO will apply its technology platform to support one of AstraZeneca's oncology programs. KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale.

5 Jan 2011

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

A study that included more than 100,000 patients who received implantable cardioverter-defibrillators (ICDs) found that about 20 percent did not meet evidence-based guidelines for receipt of an ICD, and that these patients had a significantly higher risk of in-hospital death than individuals who met criteria for receiving an ICD, according to a study in the January 5 issue of JAMA.

5 Jan 2011

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Application for ERWINAZE(R) has been accepted for filing and awarded Priority Review status by the U.S. Food and Drug Administration.

5 Jan 2011

Administration of therapeutic hypothermia for TBI should depend on clinical condition of individual patients

Lowering the body temperature of patients soon after they have suffered a severe brain injury may reduce neurologic complications and improve outcomes. The safety of therapeutic hypothermia for traumatic brain injury (TBI) has been demonstrated in national studies. According to a Roundtable Discussion of renowned experts in the field, when and how it is administered should depend on the clinical condition of individual patients.

5 Jan 2011

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Researchers from The Scripps Research Institute, Weill Cornell Medical College, and Cornell University have produced a long-lasting anti-cocaine immunity in mice by giving them a unique vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

5 Jan 2011

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye. Left untreated, these conditions often lead to impaired vision and even blindness.

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Canadian Cancer Society launches sixth annual Driven to Quit Challenge

Results of an Angus Reid Public Opinion survey conducted in December show that 20 per cent of Ontario adults are current tobacco users, including cigarettes, cigars and chew tobacco, and that half of them have tried unsuccessfully to quit in the past.

5 Jan 2011

Study identifies sailing injuries

Just as the site for the 2013 America's Cup has been announced, a study from Rhode Island Hospital highlights that the sport isn't always smooth sailing. The study was published recently in the journal Wilderness and Environmental Medicine.

5 Jan 2011

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.

5 Jan 2011

Medical Condition News

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML

Study finds fusion surgeries designed to alleviate pain from degenerating discs not effective

American Heart Association partners in global effort to prepare for UN non-communicable diseases summit

Soldiers with positive outlook in traumatic situations less likely to suffer anxiety, depression

Neuroscientist says spatial strategies can reduce risk of dementia

Predictive value of plasma galectin-3 levels in heart failure patients: Study

Study shows adolescents who were breastfed at birth have stronger leg muscles

ImmunGene, Cephalon Australia collaborate to advance new class of protein therapeutics

KINAXO, AstraZeneca enter oncology research collaboration

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

EUSA receives FDA Priority Review status for ERWINAZE BLA

Administration of therapeutic hypothermia for TBI should depend on clinical condition of individual patients

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

GLUMETZA tablets are now available to wholesalers and physicians

Canadian Cancer Society launches sixth annual Driven to Quit Challenge

Study identifies sailing injuries

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News